12/3/2024

Janusmed kön och genus

Janusmed kön och genus – Ezetimib Krka

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ezetimib

Ezetimib

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44(5):467-94

  2. Chu NN, Chen WL, Xu HR, Li XN. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. Clin Drug Investig. 2012;32:791-8.

  3. Zetia (ezetimibe). DailyMed [www]. US National Library of Medicine. [updated 2016-02-26, cited 2016-10-17].

  4. Zetia (ezetimibe). Summary of Product Characteristics. Medical Products Agency Sweden (MPA); 2003.

  5. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - ZETIA (ezetimibe). Food and Drug Administration [www]. [updated 2002-10-25, cited 2016-10-17].

  6. Thomas F Lüscher, A John Camm, Gerald Maurer, Patrick W Serruys. The ESC Textbook of Cardiovascular Medicine (3 ed). Oxford University Press; 2016.

  7. Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis. 2011;10:146.

  8. Shigematsu E, Yamakawa T, Taguri M, Morita S, Tokui M, Miyamoto K et al. Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. J Atheroscler Thromb. 2012;19:846-53.

  9. Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin. 2006;22:823-35.

  10. Averna M, Zaninelli A, Le Grazie C, Gensini GF. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. J Clin Lipidol. 2010;4:272-8.

  11. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005;179:361-7.

  12. Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. Int J Cardiol. 2011;153:141-7.

  13. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-7.

  14. Kishimoto M, Sugiyama T, Osame K, Takarabe D, Okamoto M, Noda M. Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. J Med Invest. 2011;58:86-94.

  15. Kusters DM, Caceres M, Coll M, Cuffie C, Gagné C, Jacobson MS et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166:1377-84e1-3.

  16. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-56.

  17. Green A, Ramey DR, Emneus M, Iachina M, Stavem K, Bolin K et al. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Am J Cardiol. 2014;114:1518-22.

  18. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-11-08.]

  1. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44(5):467-94
  2. Chu NN, Chen WL, Xu HR, Li XN. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. Clin Drug Investig. 2012;32:791-8.
  3. Zetia (ezetimibe). DailyMed [www]. US National Library of Medicine. [updated 2016-02-26, cited 2016-10-17].
  4. Zetia (ezetimibe). Summary of Product Characteristics. Medical Products Agency Sweden (MPA); 2003.
  5. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - ZETIA (ezetimibe). Food and Drug Administration [www]. [updated 2002-10-25, cited 2016-10-17].
  6. Thomas F Lüscher, A John Camm, Gerald Maurer, Patrick W Serruys. The ESC Textbook of Cardiovascular Medicine (3 ed). Oxford University Press; 2016.
  7. Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis. 2011;10:146.
  8. Shigematsu E, Yamakawa T, Taguri M, Morita S, Tokui M, Miyamoto K et al. Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. J Atheroscler Thromb. 2012;19:846-53.
  9. Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin. 2006;22:823-35.
  10. Averna M, Zaninelli A, Le Grazie C, Gensini GF. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. J Clin Lipidol. 2010;4:272-8.
  11. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005;179:361-7.
  12. Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. Int J Cardiol. 2011;153:141-7.
  13. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092-7.
  14. Kishimoto M, Sugiyama T, Osame K, Takarabe D, Okamoto M, Noda M. Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. J Med Invest. 2011;58:86-94.
  15. Kusters DM, Caceres M, Coll M, Cuffie C, Gagné C, Jacobson MS et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166:1377-84e1-3.
  16. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-56.
  17. Green A, Ramey DR, Emneus M, Iachina M, Stavem K, Bolin K et al. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Am J Cardiol. 2014;114:1518-22.
  18. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-11-08.]